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Abstract 
 
Objective(s)  
The aim of this study was to evaluate the expressions of two angiogenic immune-markers (CD-31 and 
VEGF), and one proliferative immune-marker (Ki-67) in oral pyogenic granulomas (PG), hemangiomas 
(Hem) and inflammatory gingivitis (IG). 
Materials and Methods 
Sixty cases of PG, Hem and IG (twenty cases each) were examined. Immunohistochemical (IHC) staining 
was performed based on routine techniques. The microvessel density (MVD) index was also evaluated.  
Results 
The male to female ratio was 1:2. The mean age was 33.3 years old (±20.52). The reactivity percentages for 
all  three  markers  (CD-31,  VEGF  and  Ki-67)  were  significantly  higher  in  PG  compared  to  Hem                
(56.8%, 13.8% and 23.0% vs. 28.3%, 7.0% and 5.4%, respectively). The mean MVD in PG was also 
significantly higher than in Hem (26.1±0.11 vs. 13.6±0.08). There was no statistically significant difference 
between PG and IG. 
Conclusion 
The current study supports the common nature of pyogenic granulomas and inflammatory gingivitis.  
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Introduction 
Angiogenesis, described as the formation of new 
blood vessels, is a basic natural process that 
occurs in both physiologic (e.g. wound healing, 
menstruation) and pathologic (e.g. diabetic 
retinopathy) conditions. Angiogenesis is 
controlled through a series of stimulating and 
inhibitory factors that tightly cooperate in order 
to maintain the homeostasis of angiogenesis. 
Alterations in this regulatory process may lead to 
insufficient (e.g. coronary artery disease or 
stroke) or excessive angiogenesis (e.g. vascular 
tumors such as pyogenic granulomas and 
hemangiomas) (1).  
Pyogenic granulomas (PG) are relatively 
common rapidly growing acquired vascular 
tumors that mostly occur on the skin and 
gingival/oral mucosa. They are characterized by 
the proliferation of capillary-sized vessels along 
with extensive edema and abundant granulation 
tissue formation. Hemangiomas (Hem) are in the 
differential diagnosis of pyogenic granulomas, 
but they show more plump endothelial cells and 
they lack the granulation tissue. Nevertheless, 
they have a very similar histological 
morphology. On the other hand, pyogenic 
granuloma shares some histological findings 
with inflammatory gingivitis (IG) that put IG 
among PG’s differential diagnosis (2).  
Attempts have been made to differentiate these 
lesions utilizing immunohistochemical (IHC) 
staining; but to date no definite comprehensive 
IHC panel has been recommended and the 
results of the few available studies are 
controversial. Not surprisingly, PG varies within 
a spectrum with Hem as a neoplastic lesion in 
one end, and IG as an inflammatory reactive 
lesion in the other. IHC based studies may also 
help to understand the supposed mechanisms 
underlying these disorders (neoplastic vs 
reactive) (3-7). 
In this study, we investigated the expression of 
two angiogenic markers (CD-31 and vascular 
endothelial growth factor, VEGF), and one 
proliferative marker (Ki-67) in PG, Hem and IG.      
 
Materials and Methods 
Patients and samples 
Twenty cases of PG, twenty cases of Hem, and 
twenty cases of IG were collected from the 
Department of Oral Pathology, Mashhad 
University of Medical Sciences in the year 2008. 
Specimens with inadequate tissue or insufficient 
fixation were excluded from the study. 
 
Immunohistochemical staining  
We performed immunohistochemical staining 
for CD-31, VEGF and Ki-67. CD-31, also 
known as platelet endothelial cell adhesion 
molecule-1 (PECAM-1), and VEGF are 
angiogenic markers widely used to identify 
vascular formations especially for the 
assessment of angiogenesis in pathologic 
phenomena. Anti-Ki-67 antibody recognizes a 
proliferation specific nuclear antigen. Ki-67 is 
routinely used as an index for cellular 
proliferation and activity (8).    
Three-µm-thick sections of representative 
formalin-fixed, paraffin-embedded tissue 
specimens were prepared. The sections were 
mounted on clean slides, previously coated with 
poly-L-lysin adhesive, then deparaffinized using 
Xylene and rehydrated in graded alcohols. 
Thereafter, the endogenous peroxidase was 
deactivated by soaking the slides in 
H2O2/Methanol solution. Antigen retrieval was 
done using trypsin. Afterwards, streptavidin-
biotin method was conducted for 
immunostainings. IHC antibodies were 
purchased from Dako Corporation: the anti-CD-
31 (clone JC/70A, Dako Corporation, North 
America, USA), the anti-VEGF (clone VG1, 
Dako Corporation, Glostrup, Denmark) and the 
anti-ki-67 (clone MIB-1, Dako Corporation, 
North America, USA). All immunostaining 
processes were carried based on the 
manufacturers’ recommendations. Finally, the 
slides were counterstained with hematoxylin. 
Positive control samples were consisted of 
colorectal tissue for CD-31 and VEGF markers, 
and tonsilar lymphoid tissue for Ki-67. Tissue 
sections without non-immune antibody served as 
the negative controls.  
 
Immunohistochemistry interpretation 
Two pathologists examined each slide 
independently. CD-31 and VEGF were 
expressed in both membrane and cytoplasm, 
while Ki-67 was expressed in the nucleus. The 
percentages of reactive endothelial cells (vs non-
reactive endothelial cells) in five high power 
fields for CD-31/VEGF, and in one hundred 
cells for Ki-67 were noted.  
The MicroVessel Density (MVD) index was 
also evaluated as described by Behrem et al (9)  
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using CD-31 stained slides. First, the tissue was 
screened at low power (40×) to identify areas of 
the highest vascularization. Second, vessels were 
counted in three such high density areas at high 
power magnification (400×). The average of the 
MVD counted by two independent observers was 
considered as the MVD of each individual lesion. 
 
Statistical analysis 
Reactivity percentages for IHC markers and 
MVD index were compared among the three 
groups corresponding PG, Hem, and IG using 
ANOVA test. Tukey post hoc test was used to 
make all the pair wise comparisons between 
these groups. Similar comparison was also made 
between capillary and cavernous hemangiomas 
conducting t-test. The data was analyzed using 
SPSS version 10.0.1. The significance level was 
set at 0.05.   
 
Results 
Patients consisted of 20 (33.3%) males and 40 
(66.6%) females with a mean (standard 
deviation, SD) age of 33.3 years old (20.52). The 
groups were statistically matched for age and sex 
(P> 0.05).  
An example of the performed 
immunostainings is demonstrated in Figure 1. 
Table 1 shows the summary statistics for 
reactivity percentages of CD-31, VEGF and Ki-
67. Reactivity for all three IHC markers was 
significantly different for the three lesion types.  
However, the post hoc analysis revealed that 
the differences of Hem from PG and IG were 
responsible for most of this variability. In fact, 
no statistically significant difference between PG 
and IG was discovered.   
For angiogenesis markers of CD-31 and 
VEGF, the reactivity percentages in PG were 
twice their reactivity in Hem (56.8% and 13.8% 
vs. 28.3% and 7.0%, respectively) (P= 0.000 and 
P =0.046, respectively). Likewise, the positivity 
for proliferating marker of Ki-67 in PG was 
more than four times higher than Hem (23.0% vs 
5.4%) (P= 0.000). VEGF and Ki-67 were absent 
in two cases of Hem. As mentioned earlier, there 
were no statistical and clinical significant 
differences between PG and IG regarding the 
IHC markers. 
Mean (95% confidence interval) 
microvascular densities in PG, Hem and IG were 
26.1 (21.1-31.1), 13.6 (9.7-17.4) and 32.2 (27.2-
37.1) respectively (P< 0.001).    
Like IHC markers, the found difference was 
mainly associated with the difference between 
Hem with the other two lesions. No difference 
was seen between PGs and IGs. Mean (±SD) 
MVD in PG was double the one in Hem 
(26.1±0.11 vs 13.6±0.08). 
Amongst twenty hemangiomas investigated, 
there were nine capillary and eleven cavernous 
hemangiomas. They were completely similar in 
CD-31, VEGF, Ki-67 expression and MVD 
count (P> 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Immunohistochemistry staining for CD-31 (above) and Ki-67 (bottom) in pyogenic granuloma (right) and 
hemangioma (left).   
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Table 1. Reactivity percentages of CD-31, VEGF and Ki-67 in PG, Hem and IG 
 
95% Confidence 
interval for mean  Antibody Lesion  N  Mean  Standard 
deviation  Lower 
bound 
Upper 
bound 
F  P-value 
PG 20  13.8  12.40 8.00  19.6 
Hem 20  7.0  5.83  4.3  9.7 
 
VEGF 
IG 20  17.4  6.71  14.2 20.5 
7.125 .002 
PG 20  56.8  21.31 46.9  66.8 
Hem 20  28.3  13.87  21.8  34.8 
 
CD-31 
IG 20  63.4  20.78 53.6 73.1 
19.348 .000 
PG 20  23.0  12.00 17.4  28.7 
Hem 20  5.4  6.65  2.2  8.5 
 
Ki-67 
IG 20  19.6  10.89 14.6 24.8 
17.257 .000 
*PG= Pyogenic granuloma, Hem=Hemangioma, IG= Inflammatory gingivitis. 
 
Discussion  
Pyogenic granulomas are benign inflammatory 
lesions displaying remarkable vascularization. 
They may present in any age, but they are 
most prevalent in the second decade of life 
with female predominance (2). The results of 
our study also confirms this informtaion 
(overall, 66% female; third decade of life). 
Few studies, such as Toida et al have reported 
an older mean age of 52.7 years (10).   
Pyogenic granulomas are typically solitary 
nodules showing a tendency towards head and 
neck and extremities especially fingers. 
However, reports exist from uncommon sites 
such as, iliac vein, larynx, liver, etc. Moreover, 
rare multiple or recurrent PGs have been 
described in the literature (11-15). 
The pathogenesis of PG remains to be fully 
understood. It has been discovered that there is a 
conceivable linkage between PG and chronic 
physical injuries (e.g. trauma, burns), insofar as 
almost one-third of PGs occur after such 
traumas. It is proposed that these injuries may 
act as potential stimuli that activate the healing 
and repair response leading to inappropriate and 
falsely regulated inflammation, angiogenesis, 
hyperplasia and consequently, improper 
granulation tissue formation; the hallmark of PG 
histopathology. Thus, PGs are suggested to be 
more reactive rather than neoplastic (2). 
Although, convincing scientific evidence does 
not exist.   
Based on these considerations, it becomes 
clear that either inflammatory response or 
angiogenesis can play a role in pathogenesis of 
PG. As a result, both inflammatory gingivitis 
(non- neoplastic) and hemangiomas (neoplastic) 
are in the differential diagnosis of PG. 
Unfortunately, these lesions also share a very 
similar histopathology and it is sometimes too 
hard to differentiate these lesions exclusively 
based on histological examination (2). In such 
conditions, IHC may provide some practical 
help. Furthermore, IHC may shed light on the 
putative underlying mechanisms of these 
lesions’ pathogenesis (reactive vs. neoplastic).    
In the current study, not only the expression of 
CD-31, VEGF and Ki-67 were significantly 
different between PG and Hem, but also there 
was a difference in their mean MVDs. These 
findings support the commonly believed 
different pathogenesis of these lesions. Besides, 
no difference was detected between PG and IG, 
confirming their common origin.  
According to Dyduch et al,  the VEGF 
reactivity and proliferative index (Ki-67) were 
higher in PG compared to Hem, to the point that 
the median of VEGF reactivity in the PG group 
was 10%-50% (++) while it was negative (-) in 
the Hem group. They also observed that the 
mean Ki-67 expression in PG was about three 
times higher than Hem. (14.13 vs 4.85) (3). 
However, in an antecedent study, the same 
authors, had discovered that the expression of 
Ki-67 did not differ significantly between these 
lesions (4). Nakamura also found that there was 
no difference in ki-67 expression between the 
lesions (5).  
In the study conducted by Freitas et al, 
VEGF expression and mirovessel density 
(MVD) using CD-31 were not significantly 
different between PG and Hem. However, the 
mean number of VEGF-positive cells in PG 
was higher compared to oral hemangioma  
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specimens (153.23 vs 115.17) (6). They 
concluded that neither VEGF immunostaning 
nor MVD quantification are not useful in the 
differential diagnosis of these lesions. In 
contrary, Yuan et al have reported the VEGF 
was more expressed in PG than healthy 
gingiva and periodontitis (7). 
 
Conclusion 
Our investigation supports the reactive nature 
of pyogenic granulomas. We recommend 
immunohistochemistry staining as a practical 
and efficient technique in order to differentiate 
pyogenic granulomas from hemangiomas.  
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